MCID: TRN015
MIFTS: 58

Transient Cerebral Ischemia

Categories: Cardiovascular diseases

Aliases & Classifications for Transient Cerebral Ischemia

MalaCards integrated aliases for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 51 14 69
Transient Ischemic Attack 12 50 51 40 69
Transient Cerebral Ischemia [ambiguous] 12
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia Nos 12
Transient Cerebral Ischaemia 12
Transient Ischemic Attacks 12
Ischemic Attack, Transient 41
Tia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:224
ICD10 32 G45.9
ICD9CM 34 435.8
MeSH 41 D002546
NCIt 46 C50781

Summaries for Transient Cerebral Ischemia

MedlinePlus : 40 A transient ischemic attack (TIA) is a stroke lasts only a few minutes. It happens when the blood supply to part of the brain is briefly blocked. Symptoms of a TIA are like other stroke symptoms, but do not last as long. They happen suddenly, and include Numbness or weakness, especially on one side of the body Confusion or trouble speaking or understanding speech Trouble seeing in one or both eyes Difficulty walking Dizziness Loss of balance or coordination Most symptoms of a TIA disappear within an hour, although they may last for up to 24 hours. Because you cannot tell if these symptoms are from a TIA or a stroke, you should go to the hospital right away. TIAs are often a warning sign for future strokes. Taking medicine, such as blood thinners, may reduce your risk of a stroke. Your doctor might also recommend surgery. You can also help lower your risk by having a healthy lifestyle. This includes not smoking, not drinking too much, eating a healthy diet, and exercising. It is also important to control other health problems, such as high blood pressure and cholesterol. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to ischemia and mini stroke, and has symptoms including sleeplessness, vertigo/dizziness and chronic pain. An important gene associated with Transient Cerebral Ischemia is ODC1 (Ornithine Decarboxylase 1), and among its related pathways/superpathways are Allograft rejection and Immune response IL-23 signaling pathway. The drugs Aspirin and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and eye, and related phenotypes are cellular and nervous system

NINDS : 50 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 72 A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by loss of blood... more...

Related Diseases for Transient Cerebral Ischemia

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 ischemia 30.6 CASP3 HSPA1A HSPA4 MAP2
2 mini stroke 11.6
3 aganglionosis, total intestinal 11.4
4 moyamoya disease 1 11.4
5 cerebritis 11.0
6 neuronitis 10.7
7 aging 10.2
8 purulent labyrinthitis 10.1 CCL2 IL1B
9 toxic encephalopathy 10.1 CASP3 GRIN2A IL1B
10 endotheliitis 10.1
11 retinitis pigmentosa 73 10.1 CCL2 IL1B
12 trypanosomiasis 10.0 CCL2 IL1B ODC1
13 cerebral artery occlusion 10.0 IL1B ODC1
14 hyperglycemia 10.0
15 internal hemorrhoid 9.9 CASP3 HSPA4
16 migraine with or without aura 1 9.9
17 meningioma, familial 9.9
18 hydrops, lactic acidosis, and sideroblastic anemia 9.9
19 multiple mitochondrial dysfunctions syndrome 5 9.9
20 brain injury 9.9
21 hypoxia 9.9
22 spinocerebellar ataxia 14 9.8 CASP3 HSPA4 HSPA5
23 occlusion precerebral artery 9.8 CASP3 HSPA1A MAP2
24 alzheimer disease 9.7
25 blood group, i system 9.7
26 progeroid short stature with pigmented nevi 9.7
27 stroke, ischemic 9.7
28 orthostatic intolerance 9.7
29 anxiety 9.7
30 middle cerebral artery infarction 9.7
31 cardiac arrest 9.7
32 chlamydia 9.7
33 transient global amnesia 9.7
34 patent foramen ovale 9.7
35 hypothyroidism 9.7
36 vascular disease 9.7
37 dermoid cyst 9.7
38 cockayne syndrome 9.7
39 pneumonia 9.7
40 adenoma 9.7
41 thyroiditis 9.7
42 amaurosis fugax 9.7
43 streptococcal group a invasive disease 9.7
44 aneurysm 9.7
45 headache 9.7
46 atrial septal aneurysm 9.7
47 malaria 9.4 CASP3 CCL2 HSPA4 IL1B ODC1
48 amyotrophic lateral sclerosis 1 9.0 CASP3 HSPA4 HSPA5 MAP2 SLC1A1

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (show top 50) (show all 89)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Maxillary Sinusitis Chronic Myocardial Ischemia
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Ischemic Heart Disease Kidney Disease
Labyrinthitis Left Bundle Branch Hemiblock

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia

Symptoms & Phenotypes for Transient Cerebral Ischemia

UMLS symptoms related to Transient Cerebral Ischemia:


sleeplessness, vertigo/dizziness, chronic pain, transient ischemic attacks, stereotypic symptoms, transient ischemic attacks, differing symptoms, amaurosis fugax, tremor, syncope, seizures, sciatica, pain, headache, edema, chest pain, back pain, angina pectoris

MGI Mouse Phenotypes related to Transient Cerebral Ischemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.65 ODC1 PTK2B SLC1A1 BAD CASP3 DRD1
2 nervous system MP:0003631 9.32 SLC1A1 BAD CASP3 DRD1 GRIN2A HSPA4

Drugs & Therapeutics for Transient Cerebral Ischemia

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
2
Angiotensin II Approved, Investigational Phase 4,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
5
Losartan Approved Phase 4 114798-26-4 3961
6
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 54680692 9908
7
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120202-66-6, 113665-84-2 60606
8
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55142-85-3 5472
9
Everolimus Approved Phase 4,Phase 2,Phase 3 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3 53123-88-9 46835353 6436030 5284616
12
Warfarin Approved Phase 4,Phase 2,Phase 3 81-81-2 54678486 6691
13
Dalteparin Approved Phase 4,Phase 2 9005-49-6
14
Cilostazol Approved, Investigational Phase 4,Phase 3 73963-72-1 2754
15
Dobutamine Approved Phase 4,Phase 3 34368-04-2 36811
16
Rivaroxaban Approved Phase 4,Phase 2,Phase 3 366789-02-8
17 Edoxaban Approved Phase 4,Phase 2,Phase 3 480449-70-5
18
Dipyridamole Approved Phase 4,Phase 3 58-32-2 3108
19
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
20
Nicotine Approved Phase 4 54-11-5 89594 942
21
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
22
Metformin Approved Phase 4 657-24-9 4091 14219
23
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 46507594 772
24
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
25
Tranexamic Acid Approved Phase 4 1197-18-8 5526
26
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
27
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
28
Acenocoumarol Approved, Investigational Phase 4,Phase 3 152-72-7 54676537 9052
29
Ticagrelor Approved Phase 4,Phase 3,Phase 2 274693-27-5 9871419
30
Allopurinol Approved Phase 4 315-30-0 2094
31
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
32
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
33
Fluvastatin Approved Phase 4 93957-54-1 1548972
34
Pravastatin Approved Phase 4 81093-37-0 54687
35
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
36
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
37
Cangrelor Approved Phase 4 163706-06-7 9854012
38
Milrinone Approved Phase 4 78415-72-2 4197
39
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
40
Propafenone Approved Phase 4 54063-53-5 4932
41
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
42
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
43
Phytonadione Approved, Investigational, Nutraceutical Phase 4,Phase 3 84-80-0 5284607 4812
44
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
45 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
46
Candesartan Experimental Phase 4,Phase 3 139481-59-7 2541
47 3-n-butylphthalide Phase 4
48 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 425)

# Name Status NCT ID Phase Drugs
1 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
2 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
3 ASCEND: A Study of Cardiovascular Events iN Diabetes Unknown status NCT00135226 Phase 4 aspirin;Omega-3-acid Ethyl Esters;Placebo Aspirin;Placebo omega-3-Ethyl Esters
4 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
5 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
6 Hypertension Control Based on Home Blood Pressure Unknown status NCT00198562 Phase 4 Amlodipine, Losartan
7 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Unknown status NCT02256683 Phase 4 Dabigatran etexilate;Phenprocoumon
8 Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack Completed NCT00931788 Phase 4 Antihypertensive agents and lipid lowering therapy
9 Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke Completed NCT00147602 Phase 4 atorvastatin
10 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
11 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
12 Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease Completed NCT00962988 Phase 4 Cost-Free Pharmacotherapy Group
13 Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial Completed NCT01559298 Phase 4 Aspirin (80 mg/d) + clopidogrel (75 mg/d);Aspirin
14 EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA Completed NCT00562588 Phase 4 Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg);ASA 100 mg qd
15 Metformin-Dipyridamole Interaction Trial Completed NCT01613755 Phase 4 Metformin, dipyridamole;Metformin
16 Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Completed NCT01166685 Phase 4
17 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) Completed NCT02348723 Phase 4 Warfarin;Dabigatran Etexilate 150mg
18 Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis Completed NCT00257283 Phase 4 Omega-3-acid ethyl esters 90
19 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
20 Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II) Completed NCT00289042 Phase 4 Enoxaparin
21 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed NCT00134160 Phase 4 Olmesartan medoxomil;Calcium channel blockers (amlodipine, azelnidipine)
22 MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure Completed NCT00262119 Phase 4
23 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
24 Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial Completed NCT01035450 Phase 4
25 Tranexamic Acid Dosing for Total Joint Arthroplasty Completed NCT02584725 Phase 4 Tranexamic Acid
26 Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan Completed NCT01069302 Phase 4 Clopidogrel;Clopidogrel;Clopidogrel;Clopidogrel
27 Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack Recruiting NCT02122718 Phase 4 Allopurinol;Placebo
28 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Recruiting NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
29 Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure Recruiting NCT03445949 Phase 4 short postimplantation dual antiplatelet therapy;extended postimplantation dual antiplatelet therapy
30 Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Recruiting NCT02594800 Phase 4 Rosuvastatin
31 Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives Recruiting NCT01563731 Phase 4 all approved antihypertensive drugs; all approved statins
32 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Recruiting NCT02826200 Phase 4 Acenocoumarol
33 Preventive Effects of Ginseng Against Atherosclerosis Recruiting NCT02796664 Phase 4
34 Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol? Recruiting NCT02983214 Phase 4 Clopidogrel;Cilostazol
35 Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD Recruiting NCT03417388 Phase 4 High dose potent statin;Evolocumab;ACE-I (lisinopril) or ARB (losartan);Aspirin
36 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation Recruiting NCT03061006 Phase 4 Dabigatran Etexilate;Warfarin
37 Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD Recruiting NCT02046460 Phase 4 Acetylsalicylic acid;vitamin K-antagonist
38 Add-on Cangrelor in STEMI-triggered Cardiac Arrest Recruiting NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
39 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Recruiting NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
40 Tranexamic Acid in Revision Total Joint Arthroplasty Recruiting NCT02877381 Phase 4
41 Milrinone Versus Dobutamine in Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
42 Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Recruiting NCT02168829 Phase 4 Rivaroxaban;Acetylsalicylic acid
43 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF Recruiting NCT02389218 Phase 4 sequential drug adjustment (propafenone, sotalol or flecainide)
44 Chronotherapy With Low-dose Aspirin for Primary Prevention Recruiting NCT00725127 Phase 4 aspirin;aspirin
45 Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy Recruiting NCT03463317 Phase 4 Acetylsalicylic acid;Clopidogrel;Dabigatran;Rivaroxaban;Apixaban;Edoxaban;Phenprocoumon;Warfarin
46 Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI Active, not recruiting NCT02640794 Phase 4 Clopidogrel;Aspirin
47 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Enrolling by invitation NCT02594995 Phase 4 NBP
48 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack Not yet recruiting NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
49 Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement Not yet recruiting NCT03284827 Phase 4 NOAC;DAPT
50 Rosuvastatin in African Americans With Cerebrovascular Disease Terminated NCT01975194 Phase 4 Rosuvastatin

Search NIH Clinical Center for Transient Cerebral Ischemia

Cochrane evidence based reviews: ischemic attack, transient

Genetic Tests for Transient Cerebral Ischemia

Anatomical Context for Transient Cerebral Ischemia

MalaCards organs/tissues related to Transient Cerebral Ischemia:

38
Brain, Heart, Eye, Retina, Spinal Cord, Kidney, Testes

Publications for Transient Cerebral Ischemia

Articles related to Transient Cerebral Ischemia:

(show top 50) (show all 455)
# Title Authors Year
1
Long-term treadmill exercise improves memory impairment through restoration of decreased synaptic adhesion molecule 1/2/3 induced by transient cerebral ischemia in the aged gerbil hippocampus. ( 29341891 )
2018
2
Protective effects of D-Limonene against transient cerebral ischemia in stroke-prone spontaneously hypertensive rats. ( 29399074 )
2018
3
Treatment with Uric Acid Reduces Infarct and Improves Neurologic Function in Female Mice After Transient Cerebral Ischemia. ( 29398531 )
2018
4
Reduced Severity of Outcome of Recurrent Ipsilateral Transient Cerebral Ischemia Compared with Contralateral Transient Cerebral Ischemia in Rats. ( 28893572 )
2017
5
Neuroprotective effects of ischemic preconditioning on hippocampal CA1 pyramidal neurons through maintaining calbindin D28k immunoreactivity following subsequent transient cerebral ischemia. ( 28761424 )
2017
6
Effects of ischemic preconditioning on PDGF-BB expression in the gerbil hippocampal CA1 region following transient cerebral ischemia. ( 28627606 )
2017
7
Vascular and Tissue Changes of Magnetic Susceptibility in the Mouse Brain After Transient Cerebral Ischemia. ( 29177950 )
2017
8
Inactivation of NSF ATPase Leads to Cathepsin B Release After Transient Cerebral Ischemia. ( 29039034 )
2017
9
Neuroprotection and reduced gliosis by pre- and post-treatments of hydroquinone in a gerbil model of transient cerebral ischemia. ( 28137511 )
2017
10
CD74-immunoreactive activated M1 microglia are shown late in the gerbil hippocampal CA1 region following transient cerebral ischemia. ( 28487994 )
2017
11
Transient cerebral ischemia induces albumin expression in microglia only in the CA1 region of the gerbil hippocampus. ( 28586018 )
2017
12
Puerarin provides a neuroprotection against transient cerebral ischemia by attenuating autophagy at the ischemic penumbra in neurons but not in astrocytes. ( 28192195 )
2017
13
Physical Exercise Improves Cognitive Outcomes in 2 Models of Transient Cerebral Ischemia. ( 28663509 )
2017
14
Transient Cerebral Ischemia Alters GSK-3I^ and p-GSK-3I^ Immunoreactivity in Pyramidal Neurons and Induces p-GSK-3I^ Expression in Astrocytes in the Gerbil Hippocampal CA1 Area. ( 28349361 )
2017
15
Neuroprotective effect of safranal, an active ingredient of Crocus sativus , in a rat model of transient cerebral ischemia. ( 28984113 )
2017
16
Dysfunction of Membrane Trafficking Leads to Ischemia-Reperfusion Injury After Transient Cerebral Ischemia. ( 29022237 )
2017
17
Metabolomic Estimation of the Diagnosis and Onset Time of Permanent and Transient Cerebral Ischemia. ( 29270918 )
2017
18
Neuroprotective effect of minocycline on cognitive impairments induced by transient cerebral ischemia/reperfusion through its anti-inflammatory and anti-oxidant properties in male rat. ( 28454931 )
2017
19
GSK-3I^ as a target for protection against transient cerebral ischemia. ( 28553165 )
2017
20
Fetal Alcohol Exposure Alters Blood Flow and Neurological Responses to Transient Cerebral Ischemia in Adult Mice. ( 27987329 )
2017
21
Effects of longa89term posta89ischemic treadmill exercise on gliosis in the aged gerbil hippocampus induced by transient cerebral ischemia. ( 28440411 )
2017
22
Prea89treatment with ChrysanthemumA indicum LinnAc extract protects pyramidal neurons from transient cerebral ischemia via increasing antioxidants in the gerbil hippocampal CA1 region. ( 28534982 )
2017
23
Protective effect of I+-terpineol against impairment of hippocampal synaptic plasticity and spatial memory following transient cerebral ischemia in rats. ( 27803783 )
2016
24
Neuroprotective effect of ischemic preconditioning via modulating the expression of cerebral miRNAs against transient cerebral ischemia in diabetic rats. ( 27635859 )
2016
25
Neuroprotection by progesterone after transient cerebral ischemia in stroke-prone spontaneously hypertensive rats. ( 27283379 )
2016
26
Dapsone improves functional deficit and diminishes brain damage evaluated by 3-Tesla magnetic resonance image after transient cerebral ischemia and reperfusion in rats. ( 27321157 )
2016
27
Increases of Catalase and Glutathione Peroxidase Expressions by Lacosamide Pretreatment Contributes to Neuroprotection Against Experimentally Induced Transient Cerebral Ischemia. ( 27209305 )
2016
28
Magnetic resonance imaging detection of multiple ischemic injury produced in an adult rat model of minor stroke followed by mild transient cerebral ischemia. ( 27815649 )
2016
29
Neuroprotection of ischemic preconditioning is mediated by thioredoxin 2 in the hippocampal CA1 region following a subsequent transient cerebral ischemia. ( 27117068 )
2016
30
Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. ( 28011393 )
2016
31
Improved long-term outcome after transient cerebral ischemia in aquaporin-4 knockout mice. ( 26767580 )
2016
32
Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia. ( 26869042 )
2016
33
Effect of Fluoxetine on Neurogenesis in Hippocampal Dentate Gyrus after Global Transient Cerebral Ischemia in Rats. ( 27496030 )
2016
34
Long-term observation of neuronal degeneration and microgliosis in the gerbil dentate gyrus after transient cerebral ischemia. ( 27000214 )
2016
35
Roles of HIF-1I+, VEGF, and NF-I_B in Ischemic Preconditioning-Mediated Neuroprotection of Hippocampal CA1 Pyramidal Neurons Against a Subsequent Transient Cerebral Ischemia. ( 27785755 )
2016
36
Neuroprotective effect of ischemic preconditioning via modulating the expression of adropin and oxidative markers against transient cerebral ischemia in diabetic rats. ( 27020247 )
2016
37
Failure in neuroprotection of remote limb ischemic postconditioning in the hippocampus of a gerbil model of transient cerebral ischemia. ( 26454372 )
2015
38
Impact of hyperthermia before and during ischemia-reperfusion on neuronal damage and gliosis in the gerbil hippocampus induced by transient cerebral ischemia. ( 25434714 )
2015
39
Transient Cerebral Ischemia Promotes Brain Mitochondrial Dysfunction and Exacerbates Cognitive Impairments in Young 5xFAD Mice. ( 26632816 )
2015
40
Permeability Parameters Measured with Dynamic Contrast-Enhanced MRI: Correlation with the Extravasation of Evans Blue in a Rat Model of Transient Cerebral Ischemia. ( 26175578 )
2015
41
Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidative-inflammatory-apoptotic pathway. ( 25721294 )
2015
42
Valeriana officinalis Extracts Ameliorate Neuronal Damage by Suppressing Lipid Peroxidation in the Gerbil Hippocampus Following Transient Cerebral Ischemia. ( 25785762 )
2015
43
Ischemic preconditioning maintains the immunoreactivities of glucokinase and glucokinase regulatory protein in neurons of the gerbil hippocampal CA1 region following transient cerebral ischemia. ( 26134272 )
2015
44
Upregulation of the GEF-H1 pathway after transient cerebral ischemia. ( 25447939 )
2015
45
Hemodynamic variability and cerebrovascular control after transient cerebral ischemia. ( 26537345 )
2015
46
Transient cerebral ischemia in an elderly patient with patent foramen ovale and atrial septal aneurysm. ( 26379429 )
2015
47
Ischemic preconditioning protects neurons from damage and maintains the immunoreactivity of kynurenic acid in the gerbil hippocampal CA1A region following transient cerebral ischemia. ( 25872573 )
2015
48
Neuroprotection and reduced gliosis by atomoxetine pretreatment in a gerbil model of transient cerebral ischemia. ( 26671145 )
2015
49
Up-Regulation of TREK-2 Potassium Channels in Cultured Astrocytes Requires De Novo Protein Synthesis: Relevance to Localization of TREK-2 Channels in Astrocytes after Transient Cerebral Ischemia. ( 25886567 )
2015
50
Monocarboxylate transporter 4 plays a significant role in the neuroprotective mechanism of ischemic preconditioning in transient cerebral ischemia. ( 26692857 )
2015

Variations for Transient Cerebral Ischemia

Expression for Transient Cerebral Ischemia

Search GEO for disease gene expression data for Transient Cerebral Ischemia.

Pathways for Transient Cerebral Ischemia

Pathways related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 CASP3 HSPA1A HSPA4 HSPA5 IL1B
2
Show member pathways
12.42 BAD CCL2 IL1B PTK2B
3 12.41 GRIN2A MAP2 NOTCH3 SLC1A1
4
Show member pathways
12.09 CCL2 IL1B KMO KYNU
5
Show member pathways
12.07 CASP3 CCL2 IL1B LCN2
6
Show member pathways
12.03 CASP3 CCL2 MAP2 PTK2B
7
Show member pathways
11.94 BAD CASP3 HSPA1A IL1B
8 11.82 CASP3 CCL2 IL1B
9 11.79 CCL2 IL1B LCN2
10 11.76 CASP3 CCL2 IL1B
11
Show member pathways
11.7 HSPA1A HSPA4 HSPA5
12 11.68 CASP3 CCL2 IL1B
13
Show member pathways
11.35 HSPA1A HSPA4 HSPA5
14 11.24 CASP3 HSPA1A IL1B
15 11.05 HSPA1A HSPA4 HSPA5
16
Show member pathways
10.98 BAD CASP3 GRIN2A SLC1A1
17 10.88 HSPA1A HSPA5 IL1B
18 10.74 CCL2 IL1B
19 10.68 HSPA1A HSPA4 HSPA5

GO Terms for Transient Cerebral Ischemia

Cellular components related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 BAD CASP3 GCKR HSPA1A HSPA4 IL1B
2 NMDA selective glutamate receptor complex GO:0017146 8.62 GRIN2A PTK2B

Biological processes related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.86 CCL2 GRIN2A IL1B PTK2B
2 response to ethanol GO:0045471 9.77 BAD GRIN2A PTK2B
3 positive regulation of cell migration GO:0030335 9.76 DRD1 HSPA5 IL1B PTK2B
4 response to drug GO:0042493 9.72 BAD CASP3 DRD1 GRIN2A PTK2B
5 cellular response to organic cyclic compound GO:0071407 9.69 CASP3 CCL2 IL1B
6 response to glucose GO:0009749 9.67 BAD CASP3 PTK2B
7 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.61 DRD1 PTK2B
8 response to hydrogen peroxide GO:0042542 9.61 BAD CASP3 PTK2B
9 long term synaptic depression GO:0060292 9.59 DRD1 PTK2B
10 chaperone-mediated protein complex assembly GO:0051131 9.58 HSPA1A HSPA4
11 dopamine metabolic process GO:0042417 9.58 DRD1 GRIN2A
12 NAD biosynthetic process GO:0009435 9.57 KMO KYNU
13 PERK-mediated unfolded protein response GO:0036499 9.55 CCL2 HSPA5
14 pyridine nucleotide biosynthetic process GO:0019363 9.54 KMO KYNU
15 long-term synaptic potentiation GO:0060291 9.54 DRD1 GRIN2A PTK2B
16 tryptophan catabolic process GO:0006569 9.52 KMO KYNU
17 tryptophan catabolic process to kynurenine GO:0019441 9.48 KMO KYNU
18 response to cocaine GO:0042220 9.43 DRD1 HSPA5 PTK2B
19 positive regulation of glucokinase activity GO:0033133 9.4 BAD GCKR
20 cellular response to organic substance GO:0071310 9.33 CASP3 IL1B MAP2
21 quinolinate biosynthetic process GO:0019805 8.96 KMO KYNU
22 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 8.8 BAD CASP3 IL1B

Molecular functions related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activator activity involved in apoptotic process GO:0008656 9.16 BAD CASP3
2 enzyme binding GO:0019899 9.02 GCKR HSPA1A HSPA5 NOTCH3 PTK2B
3 NMDA glutamate receptor activity GO:0004972 8.96 GRIN2A PTK2B

Sources for Transient Cerebral Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....